

Anti-EGFR domain III (Nimotuzumab), Human IgG1, kappa Antibody

CATALOG NO.: A2004-50 (50 µg)
A2004-100 (100 µg)

BACKGROUND DESCRIPTION: Recombinant monoclonal antibody to EGFR domain III. Manufactured using Recombinant Platform with variable regions (i.e. specificity) from the therapeutic antibody h-R3 (Nimotuzumab). This antibody binds to human EGFR and inhibits EGF-dependent clonogenic growth of NRK cells and completely blocks EGF stimulated autophosphorylation of the receptor

ALTERNATE NAMES: ERBB; ERBB1; HER1; PIG61; mENA; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; epidermal growth factor, Nimotuzumab

ANTIBODY TYPE: Monoclonal

CLONE: h-R3 (Nimotuzumab)

HOST/ISOTYPE: Recombinant / Human IgG1, kappa

IMMUNOGEN: Antibody generated by humanization of the murine antibody R3, raised against EGFR purified from placenta membranes and A431 tumors

SOURCE: CHO cells

FORM: Liquid

FORMULATION: Supplied in PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Aliquot and store at -20 °C to -80 °C. Avoid repeated freeze-thaw cycles

APPLICATIONS AND USAGE: Block, FC, IHC

Note: This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)
 Anti-EGFR (Panitumumab), Humanized Antibody (A1050)
 Anti-EGFR (Matuzumab), Human IgG1 Antibody (A1090)
 Anti-EGFR (Cetuximab), Chimeric Antibody (A1047)

FOR RESEARCH USE ONLY! Not to be used on humans.